HRP20160305T1 - Borati kao inhibitori arginaze - Google Patents
Borati kao inhibitori arginaze Download PDFInfo
- Publication number
- HRP20160305T1 HRP20160305T1 HRP20160305TT HRP20160305T HRP20160305T1 HR P20160305 T1 HRP20160305 T1 HR P20160305T1 HR P20160305T T HRP20160305T T HR P20160305TT HR P20160305 T HRP20160305 T HR P20160305T HR P20160305 T1 HRP20160305 T1 HR P20160305T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkylene
- aryl
- image
- alkyl
- compound according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40676010P | 2010-10-26 | 2010-10-26 | |
| PCT/US2011/056844 WO2012058065A1 (en) | 2010-10-26 | 2011-10-19 | Boronates as arginase inhibitors |
| EP11779904.9A EP2632927B1 (en) | 2010-10-26 | 2011-10-19 | Boronates as arginase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160305T1 true HRP20160305T1 (hr) | 2016-07-01 |
Family
ID=44913403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160305TT HRP20160305T1 (hr) | 2010-10-26 | 2011-10-19 | Borati kao inhibitori arginaze |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9233985B2 (enExample) |
| EP (3) | EP3034509B1 (enExample) |
| JP (1) | JP5909239B2 (enExample) |
| CN (2) | CN106008569B9 (enExample) |
| AU (1) | AU2011320732B2 (enExample) |
| BR (1) | BR112013010099B1 (enExample) |
| CA (1) | CA2815536C (enExample) |
| DK (1) | DK2632927T3 (enExample) |
| ES (2) | ES2568680T3 (enExample) |
| HK (1) | HK1223104A1 (enExample) |
| HR (1) | HRP20160305T1 (enExample) |
| HU (1) | HUE027317T2 (enExample) |
| IL (1) | IL225926A (enExample) |
| MX (1) | MX336381B (enExample) |
| PL (1) | PL2632927T3 (enExample) |
| RS (1) | RS54750B1 (enExample) |
| SI (1) | SI2632927T1 (enExample) |
| SM (1) | SMT201600141B (enExample) |
| WO (1) | WO2012058065A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560978B1 (en) | 2010-04-22 | 2019-01-30 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| RU2599791C2 (ru) | 2010-08-10 | 2016-10-20 | Ремпекс Фармасьютикэлз, Инч. | Циклические бороновые кислотно-эфирные производные и их использование в терапии |
| EP3034509B1 (en) * | 2010-10-26 | 2020-04-22 | Mars, Incorporated | Arginase inhibitors as therapeutics |
| CN104540836B (zh) * | 2012-04-18 | 2016-11-09 | 马尔斯公司 | 作为精氨酸酶抑制剂的环约束类似物 |
| AU2014204045B2 (en) | 2013-01-04 | 2018-10-18 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP3134546A4 (en) * | 2014-04-24 | 2017-12-06 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| US10385074B2 (en) | 2014-05-05 | 2019-08-20 | Rempex Pharmaceuticals, Inc. | Synthesis of boronate salts and uses thereof |
| WO2015171398A1 (en) | 2014-05-05 | 2015-11-12 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| AU2015264418A1 (en) | 2014-05-19 | 2016-11-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| AU2015284307A1 (en) | 2014-07-01 | 2017-02-02 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| PL410665A1 (pl) | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| WO2016149393A1 (en) * | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| AU2016281620B2 (en) * | 2015-06-23 | 2021-07-22 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PT3356413T (pt) | 2015-10-01 | 2022-04-04 | Potenza Therapeutics Inc | Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas |
| DK3368541T3 (da) * | 2015-10-30 | 2020-06-29 | Calithera Biosciences Inc | Sammensætninger og metoder til inhibiering af arginaseaktivitet |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| US11291674B2 (en) | 2016-11-08 | 2022-04-05 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| WO2018119440A1 (en) | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| KR20200008578A (ko) | 2017-05-12 | 2020-01-28 | 칼리테라 바이오사이언시즈, 인코포레이티드 | (3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법 |
| BR112020007138B1 (pt) | 2017-10-11 | 2023-03-21 | Qpex Biopharma, Inc | Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos |
| CN111491937A (zh) * | 2017-12-22 | 2020-08-04 | 广东新契生物医药科技有限公司 | 作为精氨酸酶抑制剂的杂环化合物 |
| SG11202007739XA (en) | 2018-02-17 | 2020-09-29 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| WO2019173188A1 (en) * | 2018-03-05 | 2019-09-12 | Arcus Biosciences, Inc. | Arginase inhibitors |
| US12215116B2 (en) * | 2018-03-13 | 2025-02-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| AU2019246728A1 (en) | 2018-03-29 | 2020-08-27 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
| CN112424209A (zh) | 2018-04-20 | 2021-02-26 | Qpex生物制药有限公司 | 硼酸衍生物及其治疗用途 |
| WO2019205979A1 (zh) * | 2018-04-27 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
| WO2019218904A1 (zh) * | 2018-05-18 | 2019-11-21 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、其制备方法及用途 |
| EP3810615B1 (en) | 2018-06-20 | 2026-01-28 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| EP3880685B1 (en) * | 2018-11-16 | 2025-06-18 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP3897622B1 (en) * | 2018-12-18 | 2026-01-14 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| CN113614095B (zh) * | 2019-02-06 | 2024-08-23 | 广东新契生物医药科技有限公司 | 作为精氨酸酶抑制剂的烷基硼酸类化合物 |
| MY206577A (en) | 2019-02-08 | 2024-12-24 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| US12636297B2 (en) | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP4004004A1 (en) * | 2019-07-23 | 2022-06-01 | AstraZeneca AB | Arginase inhibitors and methods of use thereof |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| US20230140132A1 (en) * | 2020-01-07 | 2023-05-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| US12637481B2 (en) | 2020-03-18 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| IL297458A (en) | 2020-05-05 | 2022-12-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| IL299612A (en) | 2020-07-02 | 2023-03-01 | Incyte Corp | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| WO2023283332A1 (en) * | 2021-07-07 | 2023-01-12 | Emory University | Uses of arginase inhibitors for managing kidney disease and cardiovascular conditions |
| WO2023191116A2 (en) | 2022-01-21 | 2023-10-05 | Opiyo Sammy Oyoo | Improved suramin methods and compositions |
| IL315647A (en) | 2022-03-17 | 2024-11-01 | Incyte Corp | Tricyclic urea compounds as Jak2 and 617f inhibitors |
| WO2024086273A1 (en) | 2022-10-21 | 2024-04-25 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2024191996A1 (en) | 2023-03-13 | 2024-09-19 | Incyte Corporation | Bicyclic ureas as kinase inhibitors |
| WO2026076207A1 (en) | 2024-10-04 | 2026-04-09 | Incyte Corporation | Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1009890A (en) | 1911-02-09 | 1911-11-28 | Michael F Brauer | Dumping attachment for headers. |
| US1006597A (en) | 1911-05-26 | 1911-10-24 | Rail Joint Co | Insulated rail-joint. |
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| DE69818675T2 (de) | 1997-07-29 | 2004-07-29 | Alcon Laboratories, Inc., Fort Worth | Galaktomannanpolymere und borat enthaltende augenarzneimittel |
| AU9797998A (en) | 1997-10-10 | 1999-05-03 | Trustees Of The University Of Pennsylvania, The | Compositions and methods for inhibiting arginase activity |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| WO2002004465A1 (en) | 2000-07-06 | 2002-01-17 | Fal Diagnostics | Methods and kits for the detection of arginine compounds |
| CA2431080A1 (en) | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| EP1915143A4 (en) | 2005-07-01 | 2009-11-11 | Univ Johns Hopkins | ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE |
| MX2009005370A (es) | 2006-11-21 | 2009-10-16 | Univ Groningen | Uso de inhibidores de arginasa en el tratamiento de asma y rinitis alergica. |
| CN101755130B (zh) | 2007-07-12 | 2012-10-17 | 山洋电气株式会社 | 双重反转式轴流鼓风机 |
| CN103191129A (zh) | 2007-10-12 | 2013-07-10 | C.T.辨析有限公司 | 治疗眼睛病症的脂氧化物类化合物 |
| US20110129456A1 (en) | 2008-05-05 | 2011-06-02 | Yaolin Wang | Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer |
| WO2010085797A2 (en) | 2009-01-26 | 2010-07-29 | The Trustees Of University Of Pennsylvania | Arginase inhibitors and methods of use |
| EP2560978B1 (en) | 2010-04-22 | 2019-01-30 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| EP3034509B1 (en) | 2010-10-26 | 2020-04-22 | Mars, Incorporated | Arginase inhibitors as therapeutics |
| RU2019121905A (ru) | 2010-12-31 | 2019-09-03 | Астразенека Юкей Лимитед | Ингибиторы аргиназы и способы их применения |
| CA2852685C (en) | 2011-10-19 | 2019-02-26 | Mars, Incorporated | Inhibitors of arginase and their therapeutic application |
| KR20140077963A (ko) | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
| CN104540836B (zh) | 2012-04-18 | 2016-11-09 | 马尔斯公司 | 作为精氨酸酶抑制剂的环约束类似物 |
| SG11201503459SA (en) | 2012-11-02 | 2015-06-29 | Pharmacyclics Inc | Tec family kinase inhibitor adjuvant therapy |
| CN105473550B (zh) | 2013-07-01 | 2019-02-15 | 百时美施贵宝公司 | Ido抑制剂 |
| WO2015061752A1 (en) | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
| CN105879030A (zh) | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| KR20170129896A (ko) | 2015-03-20 | 2017-11-27 | 새미 오유 오피요 | 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도 |
| AU2016281620B2 (en) | 2015-06-23 | 2021-07-22 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| DK3368541T3 (da) | 2015-10-30 | 2020-06-29 | Calithera Biosciences Inc | Sammensætninger og metoder til inhibiering af arginaseaktivitet |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| WO2018119440A1 (en) | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| KR20200008578A (ko) | 2017-05-12 | 2020-01-28 | 칼리테라 바이오사이언시즈, 인코포레이티드 | (3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법 |
-
2011
- 2011-10-19 EP EP16150285.1A patent/EP3034509B1/en active Active
- 2011-10-19 RS RS20160243A patent/RS54750B1/sr unknown
- 2011-10-19 CN CN201610322649.4A patent/CN106008569B9/zh not_active Expired - Fee Related
- 2011-10-19 EP EP11779904.9A patent/EP2632927B1/en active Active
- 2011-10-19 CN CN201180057717.4A patent/CN103249737B/zh not_active Expired - Fee Related
- 2011-10-19 ES ES11779904.9T patent/ES2568680T3/es active Active
- 2011-10-19 ES ES16150285T patent/ES2794006T3/es active Active
- 2011-10-19 HU HUE11779904A patent/HUE027317T2/en unknown
- 2011-10-19 AU AU2011320732A patent/AU2011320732B2/en not_active Ceased
- 2011-10-19 PL PL11779904.9T patent/PL2632927T3/pl unknown
- 2011-10-19 MX MX2013004491A patent/MX336381B/es unknown
- 2011-10-19 JP JP2013536669A patent/JP5909239B2/ja active Active
- 2011-10-19 US US13/276,806 patent/US9233985B2/en active Active
- 2011-10-19 EP EP20162218.0A patent/EP3719024A1/en active Pending
- 2011-10-19 CA CA2815536A patent/CA2815536C/en active Active
- 2011-10-19 SI SI201130766A patent/SI2632927T1/sl unknown
- 2011-10-19 BR BR112013010099-0A patent/BR112013010099B1/pt not_active IP Right Cessation
- 2011-10-19 WO PCT/US2011/056844 patent/WO2012058065A1/en not_active Ceased
- 2011-10-19 HR HRP20160305TT patent/HRP20160305T1/hr unknown
- 2011-10-19 DK DK11779904.9T patent/DK2632927T3/en active
-
2013
- 2013-04-24 IL IL225926A patent/IL225926A/en active IP Right Grant
-
2015
- 2015-02-04 US US14/614,115 patent/US9440995B2/en active Active
-
2016
- 2016-05-19 SM SM201600141T patent/SMT201600141B/it unknown
- 2016-07-12 US US15/207,902 patent/US10098902B2/en active Active
- 2016-09-23 HK HK16111212.1A patent/HK1223104A1/en unknown
-
2018
- 2018-08-21 US US16/107,087 patent/US10603330B2/en not_active Expired - Fee Related
-
2020
- 2020-02-19 US US16/794,905 patent/US11389464B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| SI2498610T1 (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| CA2992211C (en) | Prodrugs of fumarates and their use in treating various diseases | |
| HRP20150982T1 (hr) | Novi modulatori sfingozin fosfat receptora | |
| JP2013542223A5 (enExample) | ||
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20210183T1 (hr) | 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate | |
| HRP20231588T3 (hr) | Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja | |
| HRP20200876T1 (hr) | Modulatori nuklearnog transporta i njihove uporabe | |
| AR064199A1 (es) | Derivados de bencimidazol y benzotriazol como inhibidores de transcriptasa inversa no nucleosidicos composiciones farmaceuticas que los comprenden y su uso en la preparacion de un medicamento para el tratamiento o profilaxis de la infeccion del hiv-1 o del sida | |
| HRP20221294T1 (hr) | Neuroaktivni steroidi, njihovi pripravci i uporabe | |
| HRP20171175T1 (hr) | Novi triciklički spojevi | |
| HRP20171197T1 (hr) | Bifenilsulfonamidni antagonist receptora endotelina i angiotensina ii, namijenjen liječenju glomeruloskleroze | |
| RU2015131006A (ru) | ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ) | |
| JP2014513046A5 (enExample) | ||
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| BR112015003376A8 (pt) | composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
| ME02545B (me) | Inhibitori kinaza i njihova upotreba u liječenju raka | |
| HRP20251281T1 (hr) | Vmat2 inhibitor valbenazin za uporabu u postupku za liječenje neurološkog ili psihijatrijskog poremećaja kod pacijenata s teškim bubrežnim oštećenjem | |
| HRP20161103T1 (hr) | Kemijski spojevi | |
| EA201500293A1 (ru) | Антихолинэргическая нейропротективная композиция и способы | |
| EA201400183A1 (ru) | Фенил-3-азабицикло[3.1.0]гекс-3-илметаноны и их применение в качестве лекарственного средства | |
| SI2760821T1 (en) | A salt salt of an anti-inflammatory substituted cyclobutenedione compound | |
| HRP20180196T1 (hr) | Diketoni i hidroksiketoni kao aktivatori puta signalizacije katenina | |
| HRP20240351T1 (hr) | Cot modulatori i postupci za njihovu uporabu |